08:45 AM EDT, 06/04/2024 (MT Newswires) -- BridgeBio Pharma ( BBIO ) said late Monday its group 5 dose escalation in a phase 2 trial of infigratinib, an investigational therapy to treat children with achondroplasia, a growth deficiency, is showing a "continued well-tolerated safety profile."

The trial, Propel 2, demonstrated a mean increase in annualized height velocity, with a +2.51 centimeters per year at month 12, and +2.50 cm per year at month 18, the biopharmaceutical company added.

The mean upper-to-lower body segment ratio at month 18 stood at 1.88, compared with 2.02 at baseline, the company said.

There were no "treatment-related adverse events" seen during the trial, BridgeBio added.

Additionally, the company said it continues to enroll participants in Propel 3, the phase 3 trial of infigratinib in achondroplasia, which is expected to complete enrollment by the end of 2024.

BridgeBio's shares rose nearly 8.0% in recent Tuesday premarket activity.

Price: 31.29, Change: +2.31, Percent Change: +7.97